Hietanen M H
Department of Neurology, University of Helsinki, Finland.
Acta Neurol Scand. 1991 Nov;84(5):407-10. doi: 10.1111/j.1600-0404.1991.tb04978.x.
Eighteen patients with Parkinson's disease were treated with placebo for 4 weeks and with the MAO-B inhibitor selegiline for 8 weeks without levodopa in a randomized double-blind clinical study. The maximum dose of selegiline was 30 mg/day and the patients' cognitive functions were evaluated before treatment and at week 12 when they were either on 30 mg selegiline or placebo. A series of neuropsychological tests were used to study general cognitive reasoning, memory, visuospatial abilities, attention, cognitive flexibility, motor functions and depression. Specific cognitive effects were not observed. Slight improvement occurred mainly in learning (easy word associations) which may reflect a limited, nonspecific arousal effect.
在一项随机双盲临床研究中，18名帕金森病患者先接受了4周的安慰剂治疗，然后在不使用左旋多巴的情况下，接受了8周的单胺氧化酶B（MAO-B）抑制剂司来吉兰治疗。司来吉兰的最大剂量为每日30毫克，在治疗前以及第12周（此时患者服用30毫克司来吉兰或安慰剂）对患者的认知功能进行了评估。使用了一系列神经心理学测试来研究一般认知推理、记忆、视觉空间能力、注意力、认知灵活性、运动功能和抑郁情况。未观察到特定的认知效果。主要在学习方面（简单的单词联想）出现了轻微改善，这可能反映了一种有限的、非特异性的唤醒效应。
